期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 22, 期 1, 页码 9-34出版社
INFORMA HEALTHCARE
DOI: 10.1517/13543784.2013.739605
关键词
5-FU; AGS-16M18; AGS-8M4; ASP-6183; ALS-357; AMG-102; AMG-655; AMG-951; amolimogene bepiplasmid; amonafide malate; AS-1413; AZD-2461; AZD-4769; AZD-7762; AZD-8055; betulinic acid; biotope-CD; conatumumab; CVX-241; dacetuzumab; davanat-1; dulanermin; EMD-1204831; figitumumab; goserelin; IMC-EB10; IMGN-388; IPH-1101; MEDI-547; MGN-1706; OncoGel; PF-00562271; PF-03732010; PF-03758309; PF-04217903; PF-05057459; RG-7347; rilotumumab; SGN-40; SSR-97225; TAK-285; TAK-901; tenifatecan; TRX-518; XL-228; XL-888; zalatumumab; ZYC-101a
资金
- Cancer Research UK Funding Source: Medline
This year's analysis of discontinued drugs in oncology reveals that the trend of increasing numbers of candidate drug development terminations seen in recent years has continued into 2011. Thirty-seven drugs were dropped from the global oncology development pipeline in 2011, significantly more than the 28 discontinuations reported in 2010. Of note were the number of terminations reported for strategic reasons and the striking number of drugs (23) discontinued in or at the end of Phase I development. This article provides a summary of those drugs discontinued in 2011 and discusses the observations in the context of the rapid changes occurring in the way new anticancer drugs are developed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据